Regulators

NICE rebuffs Roche, BMS in round of cancer rejections

Cost-effectiveness watchdogs in the U.K. dealt another couple of blows to pricey cancer drugs. The National Institute for Health and Care Excellence gave a final thumbs-down to Roche's breast cancer med Kadcyla, despite the drugmaker's discount offer.